Avoid: All GLP-1 patches until Phase 3 clinical trials demonstrate their efficacy, which is not expected until 2030 or later, when microneedle technology may enable effective transdermal delivery of medications like semaglutide
Monitor potassium levels in patients at risk for hypokalemia, if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations)
Cells were lysed with lysis buffer (KRBH supplemented with 0.1% BSA and 1% Triton X-100), collected in an Eppendorf tube, sonicated 3X 10 seconds and centrifuged at 13,000 rpm for 10 minutes
Semaglutide GLP-1 injections were originally created for treating type 2 diabetes as it acts similarly to a hormone that our bodies naturally produce called incretin, which aids in controlling our appetite
These drugs were first made to treat Type 2 diabetes
External resources New England Journal of Medicine: Retatrutide Phase 2 Trial Results FDA Drug Safety and Availability Information For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol tools, and a community of thousands who have navigated these exact dosing decisions
